Based on the key measurements obtained from Sunshine Biopharma's financial statements, Sunshine Biopharma Warrant is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Sunshine Biopharma's Total Current Assets are fairly stable compared to the past year. Short and Long Term Debt Total is likely to climb to about 1 M in 2024, despite the fact that Retained Earnings are likely to grow to (60.7 M). Key indicators impacting Sunshine Biopharma's financial strength include:
The essential information of the day-to-day investment outlook for Sunshine Biopharma includes many different criteria found on its balance sheet. An individual investor should monitor Sunshine Biopharma's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Sunshine Biopharma.
Net Income
(4.73 Million)
Sunshine
Select Account or Indicator
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Begin Period Cash Flow
Stock Based Compensation
Depreciation
Change To Inventory
Net Borrowings
Total Cashflows From Investing Activities
Change To Account Receivables
Change To Operating Activities
Change To Netincome
Change To Liabilities
Investments
Total Assets
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Stockholder Equity
Total Liab
Total Current Assets
Common Stock
Short Long Term Debt Total
Other Current Liab
Other Assets
Other Current Assets
Short Term Debt
Property Plant And Equipment Net
Non Current Assets Total
Net Receivables
Inventory
Accumulated Other Comprehensive Income
Net Tangible Assets
Non Currrent Assets Other
Property Plant Equipment
Long Term Debt
Net Invested Capital
Short Long Term Debt
Capital Stock
Net Working Capital
Property Plant And Equipment Gross
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Income Tax Expense
Selling General Administrative
Selling And Marketing Expenses
Total Other Income Expense Net
Research Development
Depreciation And Amortization
Total Revenue
Gross Profit
Net Income Applicable To Common Shares
Net Interest Income
Net Income From Continuing Ops
Cost Of Revenue
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Sunshine Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Sunshine Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Sunshine Biopharma's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Sunshine Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sunshine Biopharma Warrant. Check Sunshine Biopharma's Beneish M Score to see the likelihood of Sunshine Biopharma's management manipulating its earnings.
Sunshine Biopharma Stock Summary
Sunshine Biopharma competes with Bausch Health, Haleon Plc, and Intracellular. Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada. Sunshine Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Sunshine Biopharma's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Sunshine Biopharma's current stock value. Our valuation model uses many indicators to compare Sunshine Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sunshine Biopharma competition to find correlations between indicators driving Sunshine Biopharma's intrinsic value. More Info.
Sunshine Biopharma Warrant is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At this time, Sunshine Biopharma's Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Sunshine Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Sunshine Biopharma Systematic Risk
Sunshine Biopharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sunshine Biopharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Sunshine Biopharma correlated with the market. If Beta is less than 0 Sunshine Biopharma generally moves in the opposite direction as compared to the market. If Sunshine Biopharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sunshine Biopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sunshine Biopharma is generally in the same direction as the market. If Beta > 1 Sunshine Biopharma moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Sunshine Biopharma is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Sunshine has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Sunshine Biopharma's financials are consistent with your investment objective using the following steps:
Review Sunshine Biopharma's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
Study the cash flow inflows and outflows to understand Sunshine Biopharma's liquidity and solvency.
Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
Compare Sunshine Biopharma's financials to those of its peers to see how it stacks up and identify any potential red flags.
Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Sunshine Biopharma's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Today, most investors in Sunshine Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sunshine Biopharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Sunshine Biopharma growth as a starting point in their analysis.
Sunshine Biopharma November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Sunshine Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sunshine Biopharma Warrant. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sunshine Biopharma Warrant based on widely used predictive technical indicators. In general, we focus on analyzing Sunshine Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sunshine Biopharma's daily price indicators and compare them against related drivers.
When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.